Table 1.

Clinicopathologic characteristics of platinum-treated NSCLC patients (n = 72) compared with median Pol η expression levels

nPol η median (range)PMSHR (95% CI)P
SexM511.03 (0.12-10.98)0.39111.44 (0.73-2.75)0.3
F211.3 (0.3-4.55)17.4
Age<63 (median)341.3 (0.21-6.02)0.4815.30.87 (0.47-1.61)0.65
≥63381.01 (0.12-10.98)13.6
HistologyAdenocarcinoma441.26 (0.31-6.02)0.11150.91 (0.48-1.71)0.76
Other280.79 (0.12-10.98)14.57
Extent of the diseaseIII270.95 (0.3-10.98)0.2215.90.66 (0.35-1.23)0.18
IV451.21 (0.12-6.02)10.1
Serum LDH<216290.92 (0.12-6.02)0.2814.570.8 (0.4-1.6)0.52
≥216291.14 (0.21-2.95)11
Smoking statusNo171.3 (0.35-6.02)0.7621.60.46 (0.26-1.01)0.05
Current/former551.07 (0.12-10.98)10.1
ECOG performance status0541.03 (0.21-10.98)0.9214.570.9 (0.43-1.83)0.7
1181.3 (0.12-2.72)7.98
Hematologic toxicityGrade 0-2441.05 (0.12-10.98)0.1515.30.52 (0.21-0.95)0.04
Grade 3 and 4201.30 (0.66-6.02)6.9
Objective responseNo471.29 (0.12-10.98)0.986.92.04 (1.15-4.13)0.01
Yes191.03 (0.4-5.32)15.9
RadiotherapyNo56111.14 (0.53-2.47)0.74
Yes1613.6
Pol ηLow3621.10.41 (0.19-0.73)0.003
High366.93
  • NOTE: Significant associations were determined by Mann-Whitney U and Kruskal-Wallis tests. The unadjusted hazard ratios for each variable were estimated by Cox regression (P values are log-rank tests). Objective responders are partial and complete responders, nonresponders are patients with stable or progressive disease.

    Abbreviations: MS, median survival (months); LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group.